Navigation Links
Interim Data From RECORD Study Show No Significant Difference,Between Avandia and Standard Therapy in Risk of Cardiovascular,Hospitalization or Death

y more cases were seen in Avandia patients - consistent with the well known association between fluid retention and TZDs, the class of medicine to which Avandia belongs. Fluid retention can worsen or lead to CHF. Importantly, despite the increase in CHF, there was no difference between the Avandia group and the control groups in the key outcome of cardiovascular hospitalizations and death.

"The interim findings do not show evidence of a significant difference in cardiovascular death and heart attack between Avandia and the control groups, and therefore do not confirm the hypothesis generated by the recently published meta-analysis in the New England Journal of Medicine that raised concerns about these events with Avandia," said Moncef Slaoui, chairman, R&D for GSK. "They add to the weight of evidence, from both previously published long-term clinical trials and other studies, that the overall ischemic cardiovascular safety profile of Avandia is comparable to the traditional anti-diabetes treatments. Patients and physicians should find these data reassuring."

Because Avandia has been shown to control blood sugar for longer than other traditional oral anti-diabetic medicines, it is an important option for physicians who often need to prescribe a combination of diabetes medicines to help their patients maintain blood sugar levels.

Professor Home, Vice President, International Diabetes Federation, University of Newcastle-upon-Tyne, UK, and chairman of the RECORD Steering Committee, said that although the study is not expected to be complete until late 2008, the committee concluded that an interim analysis should be published as soon as possible. "Ideally, we would have allowed RECORD to complete before analyzing and releasing the results," Home said. "However, in light of the questions raised recently about Avandia, we felt it critical that interim data from this important study be made available to
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting

Post Your Comments:
(Date:11/6/2009)...a., Nov. 6 In consultation with th...Consumer Healthcare, Division of McNEIL-PPC, Inc.,...ber of product lots of TYLENOL® Arthritis Pai...ed EZ-OPEN CAP. McNeil is initiating the recall af... associated with these lots that led to a small nu...
(Date:11/6/2009)...wswire/ -- Repossessions and liquidations of truck...er of 2009 declined as compared to similar figures... NasTrac Quarterly Index (NQI). The figures, cull...possessions and orderly liquidations, also indicat...nd printing equipment, offering mixed news on the ...
(Date:11/6/2009)...ewswire-FirstCall/ -- Derma Sciences, Inc. (OT...und care products, announced plans to release its ..., November 16, 2009. The Company will hold a confe... 11:00 am EST. Interested parties should call (866...onal), with passcode 81416481 to access the call. ...
Breaking Medicine Technology:McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Just Released New Poll 3A Healthcare Through Womens Eyes 60259 1Just Released New Poll 3A Healthcare Through Womens Eyes 60259 2Webmedx Reacts to News of Confidential Medical Records Being Sold on the Black Market 60255 1Webmedx Reacts to News of Confidential Medical Records Being Sold on the Black Market 60255 2VitaminSpice Appoints Dr Richard F Seelig as Director 5795 1VitaminSpice Appoints Dr Richard F Seelig as Director 5795 2
...25 Findings from an international,multicenter, ra... trial,evaluating ustekinumab (CNTO 1275) in the t...ll be presented for the first time at the 21st mee...akes place from Sept. 30 to,Oct. 5, 2007 in Buenos...O 1275 (anti-IL-12/23p40) Treatment of,Psoriasis: ...
...Drug,s Benefit, Alone and With Lipitor(R), in, O...and Triglycerides -, HAYWARD, Calif., Sept. 25 M...to the discovery and development of novel,therapeu... announced today,that it has begun a 180-patient P...tients with high cholesterol and triglycerides to ...
Other Medicine Technology:Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting 2Metabolex Begins Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia 2
(Date:11/8/2009)... Pharmaceutical Researc... President Ken Johnson released the following stat... ,, "We are disappointed, but not surprised by ...f hardworking Americans as well as nearly half of ...ho voted against the bill. ,, "While well inten...
(Date:11/8/2009)...Shows Who Sides With Working Families vs. Insuranc...wire-USNewswire/ -- On the heels of an historic la...a good, balanced health care reform bill, the Penn...tate,s U.S. representatives voted on HR 3962, the ... legislation, which passed Saturday evening by a v...
(Date:11/7/2009).... 7 Speaker Nancy Pelo...R. 3962, the Affordable Health Care for America Ac...onight. Below are the Speaker,s remarks. ,, "...ic moment for our nation and for American families...d political philosophy -- as far back as Teddy Roo...
(Date:11/7/2009)...RNewswire/ -- Calling this a "defining moment" for...resident J. James Rohack, M.D., today addressed me...e and medical specialty societies at the opening o...re health system reform will top the agenda. ,,...1209/AMALOGO ) ,, "Over the next 72 hours, th...
(Date:11/7/2009)... The U.S. bishops Novem...s to vote for the Stupak-Ellsworth Amendment to th...Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment w...funding and conscience protections in the Affordab...said. ,, The letter was signed by Cardinal Just...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
...N, Feb. 6 The U.S. Agency for,International Devel...y of,Zero Tolerance for Female Genital Cutting (FG... First Lady of the Federal Republic of Nigeria,spe...practice., Approximately 100 million to 140 milli...
...IS, Feb. 6 Worrell Inc., a full-service,product d...Shanghai, has,acquired the Montreal and San Diego ...ges Worrell Inc.,s industrial design prowess with ...ell. "We know how this business works. The Gad,Sha...
... currently expected to be February 21, 2008 ...ceived - Class action lawsuit settled...n Therapy,Services, Inc. (Nasdaq: RTSX ) (the "Co...d as of October 19, 2007 among,the Company, Radiat...
...f the Red Cross Annual Disaster Giving Program Pro...re weather and,tornadoes ripped through the South ...ommunities in Arkansas, Kentucky, Tennessee, Alaba...shelter, feeding victims and search and rescue wor...
..., Mass. (February 6, 2008)Perhaps the only positiv...a is that its relatively uncommon. Other than that...ends to strike people in the prime of their lives,...is poorly understood type of cancer. , One appro...
...N, Feb. 6 The Lupus Foundation of,America (LFA) i...atient,education series. Five new booklets and ele... information about lupus diagnosis and treatment.,... individuals and families. Developed in consultati...
Other Medicine News:Health News:From Kent Hill, USAID Assistant Administrator for Global Health on the Observance of International Day of Zero Tolerance 2Health News:Radiation Therapy Services, Inc. Shareholders Approve Merger Agreement 2Health News:Radiation Therapy Services, Inc. Shareholders Approve Merger Agreement 3Health News:American Red Cross Responds to Tornadoes in the Southeast 2Health News:Gene plays 'Jekyll and Hyde' in brain cancer 2Health News:Gene plays 'Jekyll and Hyde' in brain cancer 3Health News:Lupus Foundation of America Releases New Patient Education Series 2
...he widest offering of single-use instruments on th...long 43cm lengths for Bariatric Surgery. , Dual a...sulation covers the pivot points to reduce the cha...cord, which eliminates gapping at connection and t...
MultAcoice™™ Rongeur Handle With Ratchet and Monopolar Cautery
MultAcoice™ 5 mm Insulated Outer Shaft
...order products are offered as 1-piece or modular, ...ruments may be customized with handles of choice a...flush ports. Many standard patterns are available ...ffect delivery times. , Please Note: Individual ...
Medicine Products: